Vaderis Therapeutics closes $152M Series B financing to fund the Phase 3 HEROIC trial of engasertib, a novel oral AKT1/2 inhibitor for HHT.
Written By: Kalyani Boharapi, PharmD
Reviewed By: Pharmacally Editorial Team
Vaderis Therapeutics has closed a $152 million private Series B financing and initiated the Phase 3 HEROIC trial of engasertib in Hereditary Hemorrhagic Telangiectasia (HHT) a rare genetic vascular disorder marked by recurrent bleeding and arteriovenous malformations (AVMs). Co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, the financing provides capital expected to support operations through potential U.S. regulatory submission and approval of engasertib.
Engasertib Advances into Pivotal Development
Engasertib is an investigational oral selective allosteric inhibitor of AKT1/2. Vaderis is developing the drug to target abnormal vascular signaling associated with HHT, aiming to address underlying disease biology rather than treating individual bleeding episodes alone.
HHT affects approximately one in 3,800 people and can cause recurrent severe nosebleeds, chronic blood loss, anemia, and visceral AVMs. Despite the substantial clinical burden, no therapy has received global regulatory approval specifically for HHT. Engasertib has not yet been approved in any country for any indication.
Global Phase 3 HEROIC Study
The HEROIC trial is a randomized, double-blind, placebo-controlled Phase 3 study evaluating once-daily oral engasertib in patients with moderate-to-severe HHT. The global study will enroll participants across sites in North America, South America, and Europe.
This pivotal program follows positive proof-of-concept and long-term extension findings published in The New England Journal of Medicine. According to Vaderis, those studies demonstrated clinically meaningful and sustained improvements across multiple measures of HHT disease, laying the foundation to evaluate efficacy and safety in a larger controlled population.
“The Phase 3 study will evaluate engasertib in a larger patient population and determine whether the earlier findings can be confirmed,” said Hanny Al-Samkari, MD, Associate Professor of Medicine at Harvard Medical School and principal investigator of HEROIC.
Financing Supports Regulatory Pathway
The Series B financing marks a major increase in development capacity as Vaderis shifts from proof-of-concept studies into pivotal testing. In addition to co-lead investors Goldman Sachs Alternatives and TCGX, existing investors Medicxi and Droia participated in the round. Following the financing, Vaderis’ board includes representatives from Medicxi, Goldman Sachs Alternatives, TCGX, and Omega Funds, alongside company leadership and an independent director.
Vaderis CEO Azmi Nabulsi noted that the financing and HEROIC initiation represent a new stage for HHT drug development, with the company seeking to advance the first therapy developed specifically for the disorder.
Next Development Milestones
The immediate priority for Vaderis is the execution and enrollment of the global HEROIC Phase 3 study. Positive pivotal results could support regulatory submissions for engasertib, potentially delivering a regulatory-grade treatment option for a lifelong disorder that currently has no approved therapy.